Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial

Abstract Aims In the heart failure (HF) with preserved ejection fraction (HFpEF) PARAGON‐HF trial, sacubitril/valsartan vs. valsartan improved mortality/morbidity in patients with left ventricular ejection fraction (LVEF) below median (57%). We assessed eligibility for sacubitril/valsartan based on...

Full description

Bibliographic Details
Main Authors: Lars H. Lund, Gianluigi Savarese, Ashwin Venkateshvaran, Lina Benson, Anna Lundberg, Erwan Donal, Jean‐Claude Daubert, Emmanuel Oger, Cecilia Linde, Camilla Hage
Format: Article
Language:English
Published: Wiley 2022-02-01
Series:ESC Heart Failure
Subjects:
Heart failure with preserved ejection fraction
Heart failure with mid‐range ejection fraction
Heart failure with mildly reduced ejection fraction
Heart failure with borderline ejection fraction
PARAGON‐HF
Sacubitril/valsartan
Online Access:https://doi.org/10.1002/ehf2.13705

Internet

https://doi.org/10.1002/ehf2.13705

Similar Items